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Abstract
Despite remarkable advances in our understanding of the drivers of human malignancies, 
new targeted therapies often fail to show sufficient efficacy in clinical trials. Indeed, the 
cost of bringing a new agent to market has risen substantially in the last several decades, 
in part fuelled by extensive reliance on preclinical models that fail to accurately reflect 
tumour heterogeneity. To halt unsustainable rates of attrition in the drug discovery 
process, we must develop a new generation of preclinical models capable of reflecting 
the heterogeneity of varying degrees of complexity found in human cancers. Patient-
derived tumour xenograft (PDTX) models prevail as arguably the most powerful in this 
regard because they capture cancer’s heterogeneous nature. Herein, we review current 
breast cancer models and their use in the drug discovery process, before discussing best 
practices for developing a highly annotated cohort of PDTX models. We describe the 
importance of extensive multidimensional molecular and functional characterisation 
of models and combination drug–drug screens to identify complex biomarkers of drug 
resistance and response. We reflect on our own experiences and propose the use of a 
cost-effective intermediate pharmacogenomic platform (the PDTX-PDTC platform) for 
breast cancer drug and biomarker discovery. We discuss the limitations and unanswered 
questions of PDTX models; yet, still strongly envision that their use in basic and 
translational research will dramatically change our understanding of breast cancer 
biology and how to more effectively treat it.
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Introduction
Breast cancer (herein BC) is not a single disease, but 
is instead a collection of diseases that have distinct 
histopathological features and genetic and genomic 
variability linked to diverse prognostic outcomes. Recent 
research has highlighted this heterogeneity and defined 
ten molecular subtypes based on copy number and 
gene expression data from over 2000 patient tumours 
(Curtis et  al. 2012). Coupled with advances in our 
understanding of intertumour heterogeneity, large scale 
genomics projects such as The Cancer Genome Atlas 
(Chang et  al.  2013) and METABRIC (Pereira et  al. 2016) 
have led to unprecedented annotation of the drivers of 
BC. It is hoped that these advances will help improve 
patient stratification for targeted therapy based on the 
molecular underpinnings of individual cancer samples, 
paving the way towards personalised cancer treatment. 
However, despite the remarkable success of many such 
targeted agents, most investigational agents fail to show 
significant efficacy in clinical trials. Consequently, the 
oncological drug space suffers from 88% attrition between 
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Phase I agents and market approval (Hutchinson & Kirk 
2011). In cases where agents are initially efficacious, 
responses can be fleeting and the development of drug 
resistance is often seen as an inevitable consequence of 
cancer’s heterogeneity (Aparicio & Caldas 2013). Our 
reliance on preclinical models, unable to reflect this 
heterogeneity is therefore likely to underpin failures of 
the drug development framework (Cassidy et al. 2015).
Realising these limitations, the scientific community 
has been driven to create novel preclinical models that 
are able to recapitulate the complexity of human cancers. 
Many have turned to patient-derived tumour xenografts 
(PDTXs) (Whittle et al. 2015), which retain the complex 
heterogeneity of their originating tumour samples 
(DeRose et al. 2011, Cassidy et al. 2015, Eirew et al. 2015). 
PDTX models of BC resemble primary tumours across the 
genomic, epigenomic and transcriptomic landscape and 
are stable across multiple passages (Marangoni et al. 2007, 
Kabos et al. 2012, Eirew et al. 2015, Bruna et al. 2016). As 
preclinical models, PDTXs can be used to predict clinical 
trial responses (Gao et al. 2015); however, there use in the 
discovery phase itself has thus far been limited.
The drug discovery process is almost exclusively split 
between rational design, based on structural biology of 
the target protein and high-throughput screening (HTS). 
HTS strategies typically rely on increasingly simplified 
biological models, such as cancer cell lines containing 
reporter constructs for the pathway of interest and highly 
complex compound libraries (Kenny et al. 2015). Although 
PDTX models are undoubtedly more biologically relevant 
than cancer cell lines, they are limited by low throughput 
and high establishment costs (Siolas & Hannon 2013, 
Whittle et al. 2015).
Herein, we discuss the role of PDTX models in the BC 
drug discovery process. We begin by considering currently 
available models of BC and their uses in the drug discovery 
process before presenting the argument for increased 
use of models accurately reflecting the complexity of 
human malignancies. This complexity brings specific 
considerations, particularly in the need for high-
throughput drug combination screens and deep genomic 
characterisation of models to enable biomarker discovery. 
We conclude by reflecting on our own experiences in 
developing an integrated pharmacogenomic pipeline for 
breast cancer drug discovery using PDTX cells (or PDTCs).
Preclinical models of breast cancer
BC is a collection of diseases with distinct biological 
traits and clinical outcomes. Thus, no individual model 
would be expected to completely recapitulate human BC 
in its entirety. Nevertheless, multiple models of BC have 
been established over the years, both patient derived 
and artificially engineered. For a full overview of these 
models, including their respective limitations, the reader 
is directed to an excellent review by Vargo-Gogola and 
Rosen (Vargo-gogola & Rosen 2007). In this section, we 
consider the models most often used in basic research and 
how these have fared in the drug discovery process.
Breast cancer cell lines
BC cell lines have found extensive use in the investigation 
of proliferation, apoptosis, migration and the tumour-
initiating cell (TIC) phenomenon. The first BC cell line 
capable of surviving in culture for longer than 2 months 
was isolated in Detroit in 1970 and named MCF-7 (Soule 
et  al. 1973). This oestrogen receptor alpha (ER)-positive 
luminal cell line has been heavily relied on in the study 
of tamoxifen resistance, leading to predictive biomarkers 
of resistance in patients (Ross-innes et al. 2012). Together, 
MDA-MB-231 (a triple-negative cell line), T-47D (a luminal 
cell line) and MCF-7 account for more than two-thirds 
of all abstracts mentioning BC cell lines (Lacroix & 
Leclercq 2004). Experiments in cell lines were crucial in 
the development of one of the first targeted therapeutic 
agents launched in 1998 – the anti-HER2 Herceptin, a 
humanised antibody that binds to the ectodomain of 
HER2 (Carter et al. 1992), has demonstrated a remarkable 
clinical impact on HER2-positive BC. Cell lines have 
also helped to elucidate the mechanisms of primary and 
acquired resistance to Herceptin and are still being used 
for a significant proportion of BC research today. These 
early successes supported the use of cancer cell lines 
for both drug development and biomarker discovery 
(Heiser et al. 2012).
The artificial 2D system of in vitro culture has many 
drawbacks, and several attempts have been made to 
increase the relevance of these incredibly tractable 
models. A seminal paper published in 2003 by Al-Hajj and 
coworkers demonstrated the presence of TICs in pleural 
effusions from BC patients, which later were shown 
to be maintained in suspension as 3D spheroids called 
mammospheres (Al-Hajj et  al. 2003, Dontu et  al. 2003). 
Accumulating evidence has supported the use of this 
system to better understand the biology of specific facets 
of BC, drug resistance and metastasis (Reya et  al. 2001, 
Polyak 2002, Wicha et al. 2006). Mammosphere cultures 
have also been used to unravel molecular mechanisms 
of signalling networks, for example, those underlying 
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the apparently paradoxical role of transforming growth 
factor beta (TGFβ) in BC (Bruna et al. 2012). The authors 
further identified, using these 3D mammosphere cultures, 
that TGFβ BC subtype’s specific regulatory networks are 
dictated by epigenomic landscapes (Tufegdzic-Vidakovic 
et  al. 2015). However, as yet, no significant progress 
has been made in drug discovery using these, or other, 
complex 3D culture systems.
The tumour microenvironment (TME), comprising 
the extracellular matrix (ECM) and stromal and immune 
infiltrates, has significant bearing on the course of tumour 
development (Straussman et al. 2012, Junttila & de Sauvage 
2013). Bissell and coworkers pioneered methods to model 
the microenvironment in 3D-cultured BC cell lines (Lee 
et al. 2007). By profiling gene expression patterns, Kenny 
and coworkers were able to show that a panel of 27 BC 
cell lines more accurately reflected human tumours 
when cultured on recombinant basement membrane 
(rBM) (Kenny et al. 2007), though cells in vivo are subject 
to a plethora of ECM-derived signalling gradients not 
easily recapitulated in vitro (Cassidy 2014). The growth 
of BC cell lines as xenografts allows investigation of the 
tumour–stromal interactions seen in vivo. For example, 
Kitamura and coworkers have recently reported a 
CCL2-induced chemokine cascade that promotes 
metastasis to the lung in tail-vein-injected murine cell 
line E0771-LG (derived from a spontaneous medullary 
breast adenocarcinoma of C57BL/6 background) through 
the recruitment of metastasis-associated macrophages 
(Kitamura et al. 2015). By including stromal and immune 
components, such syngeneic cell-line xenografts can 
have substantial utility as preclinical models and in the 
drug development process.
Breast cancer mouse models
Despite not always exhibiting typical histopathological 
phenotypes seen in human BC, genetically engineered 
mouse (GEM) models have been used extensively to 
investigate tumour initiation and progression. GEM 
models generally fall into three distinct histopathological 
categories: those closely resembling non-GEM tumours, 
those with unique transgene-specific phenotypes and 
those that resemble human malignancies (Cardiff et  al. 
2000). The choice of gene promoter and the mechanism 
of induction greatly influence the histological phenotype 
of the resulting tumour, and this needs to be taken into 
consideration for all GEM studies (Cardiff et al. 2000).
GEM models driven by the mouse mammary tumour 
virus (MMTV) promoter were used to characterise 
the effects of several now widely accepted oncogenes 
and tumour suppressors in BC (including tumour 
suppressors Pten, Brca1 and Trp53 and oncogenes Erbb2, 
Myc and Ccnd1) (Vargo-gogola & Rosen 2007). When 
combined with advanced intravital imaging, GEM 
models have also been used to elucidate the precise 
role of macrophages in BC metastasis. Jeffrey Pollard’s 
Lab has relied heavily on these models to show that 
the purported metastasis-associated macrophages are 
active promoters of the metastatic cascade rather than 
bystanders (Wyckoff et al. 2007). Like syngeneic models 
of BC, GEM models have the advantage of including 
native stromal compartments of a malignancy. In this 
regard, they may outperform many patient-derived 
models (see the ‘Strategies for breast cancer drug 
discovery’ section below) in the drug discovery process. 
However, a major limitation of GEM models is their 
tendency to form ER tumours suggesting that specific 
drug discovery processes are more suitable for other 
platforms (Medina & Thompson 2000).
Heterogeneity within a clonally expanding tumour 
is a consequence of intertumour heterogeneity (intrinsic 
molecular and cellular load) and clonal evolution 
upon selective pressures, which may also occur in 
spatially distinct tumour compartments. A recent study 
has uncovered a network of inter-clonal cooperation 
maintaining intratumour heterogeneity in a Wnt-driven 
MMTV GEM BC model (Cleary et al. 2014). The authors 
simulated targeted therapy by removing Wnt1 and found 
that relapsing basal populations recruited heterologous 
Wnt-producing luminal cells to restore cooperation. 
Alternatively, tumours evolved to rescue Wnt pathway 
activation through some other mutational event. In 
each case, drug resistance occurred from the cancer cell 
autonomous compartment in a fashion that could not be 
predicted easily. If such inter-clonal cooperation exists in 
human BC, this would underline the need for polyclonal 
preclinical models. However, it is worth noting that Wnt 
is thought to play relatively minor role in human BC 
(Curtis et al. 2012).
In vitro patient-derived models of breast cancer
Realising the importance of the cancer cell autonomous 
compartment in driving therapeutic responses, many 
researchers have turned to organoid cultures to study a 
wide variety of processes involved in the development 
and disease. Beginning in 2009, the Clevers lab showed 
that single Lgr5+ intestinal stem cells (ISCs) could build 
crypt-villus structures in vitro without a supporting 
















http://erc.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
23:12
mesenchymal niche (Sato et  al. 2009). Subsequent 
research by this lab has identified culture conditions for 
normal and malignant pancreatic (Huch et al. 2013a) and 
liver (Huch et al. 2013b) organoids, amongst other tissue 
types. Organoids are generally genomically stable over 
long-term passage (Huch et al. 2015), though it is unclear 
whether mixed organoid cultures of primary tumours 
can truly recapitulate the complex clonal heterogeneity 
seen in vivo.
Recently, a biobank of 20 human colorectal carcinoma 
(CRC) organoids was established and characterised by 
exome sequencing, RNA expression analysis and high-
throughput drug screening (van de Wetering et al. 2015). 
The authors show that CRC organoids largely recapitulate 
most features of the originating tumour sample, and the 
biobank captures most of the mutational and expression 
landscapes observed in large CRC studies. The authors 
screened these cultures using an 83 compound library 
to identify the molecular signatures associated with 
drug responses (van de Wetering et  al. 2015). Although 
this study represented an important step forward for the 
field, cancers exist as communities of competing and 
cooperating clones surrounded by infiltrating stromal 
and soluble growth factors (Tabassum & Polyak 2015), 
each of which contributes to intratumour heterogeneity 
and therefore treatment response. It is therefore likely 
that in  vitro co-culture techniques would have to be of 
exquisite complexity to maintain cancer cells in a niche 
as suitable as that found in a murine host.
Patient-derived tumour xenografts
Arguably the model best reflecting the complexity of 
human malignancies is the patient-derived tumour 
xenograft (PDTX). In this model, BC clinical samples are 
implanted and propagated in highly immunodeficient 
mice, typically NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ) or 
NRG (NOD.Cg-Rag1tm1Mom IL2rgtm1Wjl/SzJ) strains. Early 
BC PDTX studies suffered from low transplantation 
efficiencies and consequently a limited diversity of 
models (Vargo-gogola & Rosen 2007, Siolas & Hannon 
2013); for example, one study reported only three ER+ 
models in a cohort of 32 stably transplantable PDTXs 
(Zhang et  al. 2013). Clearly, to be useful as preclinical 
models, the early bias towards aggressive triple-negative 
BCs (TNBCs) has to be overcome. In this context, a new 
protocol involving intraductal injection of cells in female 
mice has been developed with the hope to dramatically 
increase engraftment rates especially in less-aggressive 
tumour samples (Sflomos et al. 2016).
PDTXs reflect the originating sample’s morphological 
and molecular features, and these remained stable 
throughout serial passaging (Bergamaschi et  al. 2009, 
DeRose et al. 2011, Bruna et al. 2016). Remarkably, PDTXs 
are also a community of clones of varying degrees of 
complexity to that found in the clinical population 
(Eirew et  al. 2015, Bruna et  al. 2016). Moreover, our 
recent observations also showed that most of the clonal 
composition of a given BC-originating sample prevailed 
in the matched PDTX.
The most obvious limitation of the PDTX model is the 
lack of a functional immune system. Recent studies have 
highlighted both the essential role of the immune system 
in tumour progression (Gajewski et  al. 2013) and the 
utility of targeted therapies designed to activate immune 
components (Gubin et  al. 2014). The necessity of using 
severely immunocompromised mice as host animals 
severely limits the investigation of such therapies in PDTX 
models. Likewise, the tumour microenvironment in the 
PDTX model typically lacks patient-matched stromal cells, 
which can confer resistance to cytotoxic and targeted 
therapies (Straussman et al. 2012). We, and others, have 
found that human stromal cells are replaced by murine 
equivalents upon engraftment in the mouse, suggesting 
that implanted human cells retain the ability to recruit 
murine accessory cells to their niche (Bruna et al. 2016). 
However, it should be noted that differences exist between 
ligand repertoires of human and murine fibroblasts 
(Mestas & Hughes 2004). Clearly, stromal architecture and 
activity are mimicked in the murine host; however, it is 
currently unclear how this reflects the human TME with 
regards to supporting tumour growth and development.
The advantages of the PDTX over traditional BC 
models have been discussed extensively both here and 
elsewhere (Siolas & Hannon 2013, Whittle et  al. 2015). 
However, as with any model system, we must be clear of 
their limitations and learn to interpret preclinical findings 
within this context. For a detailed discussion of the 
limitation of the PDTX model, we direct the reader to a 
prior review by the authors Cassidy et al. (2015). Although 
the tumour’s stromal compartments are undoubtedly 
important in drug response, the most important factor 
is undoubtedly the composition of the cancer cell 
autonomous compartment. Thus, PDTX models are likely 
the most powerful models currently available in the BC 
drug discovery process, and every effort should be made 
to adapt their use to high-throughput screens.
Recently, a PDTX-based drug screening program 
of unprecedented scale was reported (Gao et  al. 2015). 
A large collection (n = 1075) of molecularly annotated 
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PDTXs derived from the most common adult cancer types 
was shown to capture the genomic and transcriptomic 
features of tumours seen in the clinical population as 
a whole. The majority of PDTXs in this collection were 
treated with a variety of targeted compounds in a strategy 
dubbed ‘1 × 1 × 1’ for ‘one animal per model per treatment’. 
This approach mimics the reality of human clinical trials, 
which do not allow for technical or biological replicates. 
One of the key findings of this study was that a population 
of PDTXs mimicked the spectrum of human clinical 
responses, reinforcing the translatability of these models 
to predict population-based drug responses. Moreover, 
known mechanisms of resistance were identified by this 
strategy; for example, three PDTXs treated with encorafenib 
developed resistance through BRAF amplification – a 
clinically relevant resistance mechanism (Shi et al. 2014). 
It follows that there is a strong rationale for performing 
drug screens in PDTX models to investigate population-
based treatment responses.
Strategies for breast cancer drug discovery
Despite increasing knowledge of the molecular structure of 
target proteins and a corresponding increase in the ability 
to design candidate therapeutics in silico, HTS are still 
essential in the drug discovery process. In order to reduce 
variability in HTS results, isogenic preclinical models 
have long been preferred in this regard. However, we have 
seen in the previous section how such in vitro models are 
not the most faithful reflections of the biological reality, 
and several steps can be taken to incorporate patient-
derived material into this process (Fig. 1). In this section, 
we  consider the impact of tumour heterogeneity on 
treatment response and explore at which points PDTX 
models may be introduced into the drug discovery process.
Tumour heterogeneity
Complex patterns of inter- and intra-tumour hetero-
geneity are a defining feature of human malignancy. 
Although the past few years have seen an unprecedented 
increase in research into tumour heterogeneity, we are 
far from a complete understanding. Indeed, current 
opinions suggest that cancer is better seen as community 
of co-existing and co-operating cells than a disease 
of a specific cell type (Tabassum & Polyak 2015). The 
origins of this heterogeneity are diverse, but Darwinian 
evolution of clonal populations has seen the most 
research in the context of treatment response. Moreover, 
a varying degree of intratumour heterogeneity exists in 
triple-negative BCs at diagnosis (Shah et al. 2012). Aside 
from the prognostic features of specific rare subclones 
(Diaz et al. 2012), there is an association between clonal 
diversity and treatment resistance for at least some 
tumour types – notably ovarian (Bashashati et al. 2013) 
and oesophageal (Maley et  al. 2006). Basal-like TNBCs 
have previously been linked with shorter disease-free 
survival compared with non-basal-like TNBCs and tend 
to be associated with a higher clonal diversity (Shah 
et al. 2012, Pereira et al. 2016). Together with the clinical 
observation that targeted therapies often fail to show 
a sustained and complete response (Aparicio & Caldas 
2013), it is apparent that intratumour heterogeneity plays 
a crucial role in treatment responses. Recently,  spatial 
Figure 1
High-throughput drug screen using patient-derived material. Figure 1 highlights high-throughput screening approaches using patient tumour material. 
(1) represents in vitro culture of tumour explants (for example as organoids/tumoroids). (2) represents the integrated PDTX:PDTC platform developed by 
our lab. In this strategy, patient tumour material is passaged and maintained in the murine host, and patient-derived tumour cells (PDTCs) are 
periodically dissociated for short-term ex vivo culture and high-throughput drug screens.
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and temporal heterogeneity, with a mark remodelling 
of tumour clonal architecture, has been observed in 
response to aromatase inhibition in BC tumours (Miller 
et al. 2016). Thus, for a more effective oncological drug 
development process, we should ensure that preclinical 
models preserve the clonal architecture of the originating 
tumour sample, and second, that combinatorial drug 
treatment regimens are investigated to simultaneously 
target multiple clonal populations and extend time 
to recurrence.
In the context of targeting multiple specific clonal 
populations within a tumour, the use of patient-
derived preclinical models retaining cancer’s polyclonal 
architecture is essential. Several groups have attempted to 
define the clonal structure within PDTX models through 
mutational clustering by population- and single cell-based 
computational approaches (Fischer et al. 2014, Eirew et al. 
2015). We have recently quantified heterogeneity in a 
large biobank of BC PDTXs using statistical tools such 
as the MATHs score (Mroz & Rocco 2013) and PyClone 
(Roth et al. 2014). PDTXs display a range of heterogeneity 
similar to that found in the clinical population. PDTXs 
also preserve most of the originating sample’s intratumour 
clonal architecture (Eirew et al. 2015, Bruna et al. 2016). 
Clonal changes occur to some extent, which were more 
prominent upon initial engraftment into the mouse than 
serial passaging, yet these rarely contained breast cancer 
driver genes (Bruna et al. 2016, Pereira et al. 2016). In line 
with previous hypothesis that specific genetic alterations 
act as markers of fitness and drive evolutionary trajectories, 
we observed that clonal dynamics are replicated in 
different mice concurrently engrafted with spatially 
separated biopsies of the same sample (Eirew et al. 2015, 
Bruna et al. 2016). These features position PDTXs as the 
only preclinical models, currently available, which are 
able to mimic the intratumour heterogeneity found in 
the cancer of origin (Cassidy et al. 2015). However, further 
studies are needed to unravel whether the patterns of 
clonal trajectories seen in PDTX models resemble those 
seen in the patient.
Combination drug screens
Resistance to therapy can occur because of differing 
sensitivity to targeted agents or differing reliance 
on oncogenic signalling pathways between clonal 
populations of the same tumour. Although it is often the 
case that resistant populations exist in a tumour before 
treatment, acquisition of new mechanisms of resistance 
can occur as a consequence of tumour evolution. For 
example, Hata and coworkers have recently shown that 
acquired resistance of epidermal growth factor receptor 
(EGFR)-mutant non-small-cell lung cancers to anti-EGFR 
therapy can occur through the genetic evolution of 
initially EGFRT790M-negative drug-tolerant cells (Hata et al. 
2016). These de novo mutant cells had a distinct phenotype 
from pre-existing resistant EGFRT790M populations, 
and drug sensitivity could be restored by co-treatment 
with Navitoclax, a BCL-2 inhibitor. Thus, tumours are 
dynamic, constantly evolving populations, and successful 
combination therapies may be hard to predict from single 
genomic characterisation.
In a large PDTX study referenced earlier (see the 
‘Patient-derived tumour xenografts’ section above), 
combination therapy resulted in longer disease-free 
survival compared with single agent therapy (Gao et al. 
2015). A good example of this is the combination of 
CDK4/6 inhibitor (LEE011) and PI3K inhibitor (BYL179) 
in BC models, which showed increased efficacy relative 
to single-agent treatment. Similar results were seen 
in melanoma PDTXs with LEE011 and Encorafenib. 
Although the benefits of using combination therapy to 
reduce proliferation and apoptosis are well explored, 
another advantage is delaying the onset of drug 
resistance. Significantly, some PDTXs treated with 
LEE011 and Encorafenib combination failed to develop 
resistance under continuous treatment for up to 200 
days. In another combination study conducted by Xu 
and coworkers, a synergistic effect was observed with 
MK-8869 and MK-2206 (mTOR and AKT inhibitor, 
respectively) in two BC PDTXs with high levels of 
AKT phosphorylation and loss of PTEN expression. 
MK-2206 was shown to inhibit AKT activation induced 
by MK-8869, suggesting that combination therapy 
is essential in tumours with cross-talking signalling 
pathways (Xu et  al. 2013). These and other studies 
strengthen the opinion that drug combinations are 
essential for more efficacious treatments.
Because PDTX models of BC preserve the clonal 
architecture of the originating tumour sample, they are 
greatly suited to study drug–drug combination screens. 
Although known co-operating signalling pathways (such 
as MET amplification and EGFR mutation in non-small-
cell lung cancer) (Bhang et  al. 2015) may be simulated 
in cell line models, the use of PDTX models that mimic 
human cancer’s complexity and dynamics ensures that 
our ability to identify novel, clinically relevant, targeted 
strategies is maximised.
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Predictive biomarker identification
Recent work has highlighted the differential prognostic 
outcome of mutations in the same gene between patients 
belonging to different integrative subtypes (Pereira et al. 
2016). The complex intertumour heterogeneity seen in 
BC means that drug screens are unlikely to identify novel 
therapies effective across all patients. Thus, it is essential 
that we develop large biobanks of PDTX models and 
deeply characterise them across genomic, transcriptomic 
and epigenomic spaces. It has been suggested that 
PDTX models are derived for each patient seen in the 
clinic and that these personalised PDTX models could 
be used to inform treatment decisions on a case-by-
case basis (Malaney et  al. 2014). However, this view 
needs to be taken with caution as there are still many 
unanswered questions that require further investigation. 
In the interim, efforts should be focussed on developing 
robust predictive biomarkers of both drug sensitivity and 
resistance to extrapolate results from a limited number 
of models to the BC population as a whole. It is our view 
that this stratified approach to treatment will be more 
effective in the near term.
Single-gene mutations are perhaps most widely adopted 
as clinical biomarkers of response (Garnett et al. 2012). As 
an example, mutations in EGFR, FLT3 and PIK3CA predict 
to some extent the efficacy of targeted therapies directed 
against the respective mutant proteins (O’Farrell et  al. 
2003, Lynch et al. 2004). In other instances, single-gene 
biomarkers can give insight into the interplay between 
the drug’s mechanism of action and the tumour’s genetic 
makeup. For example, TP53 is an important mediator 
of apoptosis and cell cycle arrest through its protein 
product p53. Inactivation of TP53 through mutation 
confers resistance to Nutlin-3a, an inhibitor of the MDM2 
E3-ligase, which negatively regulates p53 protein levels 
(Vassilev et al. 2004, Garnett et al. 2012). Similarly, RB1 loss 
and high p16Ink4a levels confer resistance to Palbociclib, 
a selective CDK4/6 inhibitor showing promising clinical 
results in ER + BC (O’Leary et al. 2016). Mutations in the 
ligand-binding domain of ESR1 itself have been found in 
several cases of metastatic ER + BC after treatment with 
antiestrogen therapy (Robinson et  al. 2013, Toy et  al. 
2013), but Fulvestrant is potentially effective in such ESR1-
mutant cells (Li et al. 2013, Merenbakh-Lamin et al. 2013, 
Toy et al. 2013). Clearly in cases such as these, biomarkers 
of drug response consisting of single mutational events 
are relatively easily understood and implication in the 
clinic can be swift. Unfortunately, single-gene drug 
response associations are uncommon, suggesting complex 
molecular circuits underlie sensitivity to therapy.
Poly(adenosine diphosphate-ribose) polymerase 
(PARP) inhibitors in ovarian cancer patients have provided 
one of the best examples to date of stratification based 
on biomarkers of drug response. PARP inhibitors exert 
their cytotoxic effect by modulating the repair of DNA 
damage (Lord & Ashworth 2012). Although originally 
developed as chemosensitisers, these compounds induce 
synthetic lethality in tumour cells from patients carrying 
germline loss-of-function mutations in DNA damage 
pathway tumour suppressor genes BRCA1 and BRCA2 
(Lord & Ashworth 2012). Several evidence suggests that 
the benefit of PARP inhibitors is not restricted to germline 
BRCA1/2 mutants and could be associated with a wider 
range of disrupted mechanisms. Hence, efforts have 
focussed on establishing a refined BRCAness signature 
(molecular signatures that mimic the phenotype seen in 
a BRCA1/2 germline loss-of-function mutation context) 
that can better identify patients who would benefit 
from PARP inhibition treatments (Turner et  al. 2004, 
Konstantinopoulos et al. 2010).
Identification of complex genomic/epigenomic 
correlates of drug sensitivity requires unbiased and 
extensive genomic profiling of resistant and sensitive 
models (Fig.  2). For example, by applying elastic net 
regression (Zou & Hastie 2005) to genomewide expression 
data, Garnett and coworkers were able to identify 
cooperative interactions associated with drug resistance 
in the NCI60 cell line panel (Garnett et  al. 2012). 
Interestingly, the authors observed several instances 
where transcriptional features correlated with drug 
sensitivity more than mutational events. For example, 
Lapatinib (an EGFR/ERBB2 inhibitor for HER2-positive 
BC) sensitivity unsurprisingly correlated with ERBB2 
expression and mutation status, but the strongest correlate 
was expression of the matrix metalloproteinase MMP28. 
Likewise, together with BRAF mutation, sensitivity to 
RAF or MEK1/2 inhibitors was recurrently associated 
with 67 features, including expression of the MAP kinase 
signalling regulators SPRY2 and DUSP4/6 (Hanafusa et al. 
2002, Garnett et al. 2012).
Clearly, biomarkers of treatment response and 
the emergence of resistance are essential to relate the 
findings from a limited biobank of PDTX models to 
the BC population as a whole. This becomes vastly 
more difficult when attempting to systematically 
identify correlates of sensitivity from combination drug 
screens across models that are themselves dynamic, 
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heterogeneous and constantly evolving. Thus, it is 
essential that PDTX biobanks are characterised and 
annotated across genomic, epigenomic, transcriptomic 
and proteomic spaces and that bioinformatics pipelines 
are incredibly robust and reproducible across labs and 
through time.
An integrated pharmacogenomic platform 
for drug discovery
The previous two sections have described the key features 
of an ideal BC drug screening program. Over the last 5 
years, our lab has developed a successful, robust and 
reliable framework for the generation of breast cancer 
explants annotated with extensive molecular data (Bruna 
et al. 2016). Each model has been extensively characterised 
across genomic, transcriptomic and epigenomic spaces 
showing that these resemble the originating cancer. The 
extensive data generated represents a valuable resource to 
the scientific community, which can be easily browsed 
using a purpose-built web portal (http://caldaslab.cruk.
cam.ac.uk/bcape).
During this time, we have refined our tumour 
engraftment protocol and now have a large biobank of BC 
PDTX samples that comprises almost equal percentages 
of originating primary and metastatic tumour samples. 
Modifications in the implantation protocol have 
included, but are not limited to dissociation of tumour 
samples to single cells with or without in vitro culture 
before implantation and alteration in implantation 
substrate. Interestingly, speed of implantation after 
collection in theatre (30–180 min) has been perhaps our 
most important protocol refinement to date, translating 
into significantly increased engraftment efficiencies and 
consequently a more thorough representation of all BC 
subtypes across the BC PDTX biobank, although with a 
bias towards ER-negative and poorer prognosis ER-positive 
tumours (Bruna et al. 2016).
A significant limitation of PDTXs as a preclinical 
platform is the fact that in vivo studies are not well 
suited for high-throughput drug screening due to 
financial and animal welfare reasons. We have recently 
reported a method for isolating single-cell suspensions 
from PDTX tumours for short-term cultured assays 
Figure 2
Biomarker discovery using PDTX models. Figure 2 highlights an unbiased approach for biomarker discovery. (1) a mixed cohort of PDTX models is 
screened with multiple compounds affecting different members of the same signalling pathway and are subsequently clustered based on responders 
and non-responders. Genomic correlates of drug response are computed before validation in vivo (2).
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(Bruna et al. 2016). These PDTX cells (or PDTCs) resemble 
the originating sample across genomic, epigenomic 
and transcriptomic landscapes and show similar 
intratumour clonal architectures. This PDTX/PDTC 
platform ensures the maintenance of the human BC in 
vivo in the mouse, while allowing for ex vivo short-term 
cultures for single and combination HTS. As a proof of 
principle, a selection of 22 PDTXs were screened for over 
100 different compounds relevant to cancer treatment 
and the observed drug responses highly correlated across 
technical and biological replicates. Similarly, compounds 
with similar target specificities or mechanism of action 
also had similar responses across all models tested. For 
example, similar responses were observed in 14 out of 
the 19 models tested with PARP inhibitor BMN-673 and 
Cisplatin (a DNA cross-linking agent), both of which 
exert their effects by increasing the frequency of mis-
repaired double-strand breaks in the absence of effective 
homologous recombination. Also, inhibitors of the PI3K-
AKT-mTOR pathway shared a similar pattern of response 
across all samples tested. To extend these observations, 
we computed the correlation scores of drug responses 
for all pair of compounds affecting the same pathway 
and observed that most compounds with overlapping 
specificity had similar responses, supporting the biological 
robustness of our data (Bruna et al. 2016). Recognising the 
importance of combination therapies in achieving long-
lasting responses (Friedman et al. 2015), we also tested and 
validated the PDTX/PDTC platform in a HT combinatorial 
drug screen with standard-of-care chemotherapeutic 
agents (Cisplatin and Paclitaxel) and six clinically relevant 
BC-targeted compounds. Remarkably, 33 of 40 (82.5%) 
drug responses tested ex vivo in PDTCs were recapitulated 
in vivo using PDTXs. We propose the use of the 
PDTX/PDTC platform as a resourceful intermediate in the 
drug discovery process before in vivo testing using PDTXs 
(Bruna et al. 2016).
Finally, to extrapolate our data to the BC population 
as a whole and to aid in patient stratification during 
therapy, we sought to identify biomarkers of resistance and 
response in our models. Analysis of the multidimensional 
data generated for each model was performed to 
identify known and novel biomarkers of drug response. 
Significantly, the PDTX/PDTC platform could identify 
known mechanisms of drug response and resistance. 
However, the heterogenous nature of plausible biomarkers 
of drug response spread across the models tested suggests 
that integrated genomic data will be a stronger predictor 
of drug response than single-gene biomarkers.
It is our belief that the integrated pharmacogenomics 
PDTX/PDTC platform will show the greatest utility in 
preclinical studies and will considerably shorten the 
time of testing new drugs in patients (Bruna et al. 2016). 
This approach extends the predictive value of PDTX 
models in oncological drug development by allowing HT 
screening of hundreds of compounds, as well as reducing 
considerably the financial costs and number of animals 
used in such studies.
Conclusions and future directions
The oncological drug space suffers from an unsustainable 
rate of attrition, in part attributed to preclinical models 
that fail to accurately represent the complexity of BC. 
BC PDTX models broadly maintain the heterogeneity of 
their originating patient tumour; however, historically 
they have suffered from considerable engraftment 
bias towards TNBCs. Although the lower-fidelity BC 
models (cell lines etc.) have long been used in the drug 
discovery process, the inherent low throughput of PDTX 
models has also limited their adoption. In the context 
of clonal diversity and intertumour heterogeneity, it is 
essential that we adapt the models best reflecting their 
originating sample to the drug discovery process. Here, 
we have considered BC models currently used in the drug 
discovery process and reflected on our own experiences 
in adapting BC PDTX models to HTS in our integrated 
PDTX/PDTC platform (Bruna et al. 2016). Efforts such as 
these can only be achieved if the establishment of PDTX 
models is shared across large collaborative networks such 
as the EuroPDX consortium (Hidalgo et al. 2014) or in the 
context of large pharmaceutical companies. Alternatively, 
the process of establishing and maintaining large cohorts 
of PDTX models might be best suited to pharmaceutical 
companies (Gao et al. 2015).
The current generation of PDTX models is unlikely 
to be their final iteration. It is important to stress areas 
where improvements can be made and emphasise that no 
single model system can represent fully the complexity 
of a human malignancy. Ideally, the next generation 
of PDTX models would incorporate tumour extrinsic 
compartments of the microenvironment specific to the 
patient, either in the form of matched patient peripheral 
blood leukocytes or matched patient fibroblasts. These 
humanised PDTX models (huPDTX) would significantly 
increase the utility of the model and perhaps decrease 
the selective pressures seen on engraftment. However, the 
generation of huPDTX models is fraught with difficulties, 
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and technical challenges are yet to be overcome (Cassidy 
et al. 2015). An intermediate solution to screen targeted 
therapies with an essential immune component could be 
to isolate and expand patient-derived peripheral blood 
leukocytes and incorporate them into complex short-
term co-cultures with PDTCs. The use of checkpoint 
inhibitors in BC is of paramount interest (Ali et al. 2015) 
and as such this strategy could be of substantial utility in 
future drug screens.
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